Dr. Noy on Next Phase of a Trial With Devimistat in Relapsed/Refractory Burkitt Lymphoma

Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next phase of a trial with devimistat (CPI-613) in patients with relapsed/refractory Burkitt lymphoma.

Noy is the primary investigator of a phase 2 trial that is evaluating devimistat in patients with relapsed/refractory Burkitt lymphoma. The study investigators are hoping to show at least a 10% response rate in both cohorts of patients on the trial: those with Burkitt lymphoma and those with high-grade B-cell lymphoma.

The next phase of the trial would be to accrue a total of 17 patients to each cohort and demonstrate further efficacy. Positive results could serve as the basis for an FDA registration in this setting where there are no alternative treatment regimens for patients, says Noy.

In addition, devimistat could become a bridge for autologous stem cell transplant (SCT) or allogeneic SCT, which would give patients a curative option, adds Noy.

Furthermore, if the drug shows favorable outcomes in the relapsed/refractory setting, it could potentially be moved into the frontline setting for patients with peripheral blood bone marrow or leptomeningeal disease, concludes Noy.